目前日期文章:201106 (6)

瀏覽方式: 標題列表 簡短摘要

I. Congenital
Hartnup disease

皮膚科劉權毅醫師 發表在 痞客邦 PIXNET 留言(0) 人氣()

Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody

皮膚科劉權毅醫師 發表在 痞客邦 PIXNET 留言(0) 人氣()

November 24, 2009 (San Diego, California) — A new fully human monoclonal antibody (MAb) against TNF, golimumab (CNTO148, Centocor/Schering-Plough), is close to entering the market. Results from a phase2 clinical trial of 172 patients with rheumatoid arthritis (RA) show encouraging safety and efficacy data, investigators reported at the 2005 ACR/ARHP Annual Scientific Meeting [ 1 ]. Phase 3 studies of RA, psoriatic arthritis, and ankylosing spondylitis are planned to start soon, the companies tell rheuma wire . Golimumab could be launched in 2007.
 

皮膚科劉權毅醫師 發表在 痞客邦 PIXNET 留言(0) 人氣()

Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of TH2-type cells in lesional skin. Thymus and activation-regulated chemokine (TARC/CCL17) is a chemokine that attracts CC chemokine receptor 4–positive (CCR4+) or CCR8+ cells. Objective: The purpose of this study was to investigate the participation of TARC in AD. Methods: We measured serum TARC levels in 40 patients with AD, 20 healthy control subjects, and 20 patients with psoriasis. We also examined disease activity by using SCORAD score; serum soluble E-selectin, soluble IL-2 receptor, IgE, and GM-CSF levels; and eosinophil numbers in peripheral blood, as well as correlations between TARC levels and these factors. The positivity of CCR4 of CD4+CD45RO+ cells in PBMCs was examined by using FACS analysis. Immunohistochemical staining of TARC and GM-CSF was performed in the lesional skin of patients with AD. Results: The serum TARC levels of patients with AD were significantly higher than those of healthy control subjects and patients with psoriasis. The serum TARC levels significantly correlated with eosinophil number (r = 0.61), SCORAD score (r = 0.60), and serum soluble E-selectin levels (r = 0.58) and weakly correlated with serum soluble IL-2 receptor levels (r = 0.34) in patients with AD. The TARC levels of patients with AD decreased after the treatment in accordance with the improvement of clinical symptoms. The CCR4 positivity of CD4+CD45RO+ cells in PBMCs of patients with AD was also higher than that of healthy control subjects. Immunohistochemical staining revealed that TARC was positive in ke-ratinocytes in the epidermis and in vascular endothelial cells, T cells, and dendritic cells in the dermis. Conclusion: Serum TARC levels are associated with disease activity of AD, and TARC may play an important role in the pathogenesis of AD. (J Allergy Clin Immunol 2001;107:535-41.)

 

皮膚科劉權毅醫師 發表在 痞客邦 PIXNET 留言(0) 人氣()

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). Dermatologists may use this tool before and after treatment to determine whether the treatment has been effective.

Area

To determine extent, the sites affected by eczema are shaded on a drawing of a body. The rule of 9 is used to calculate the affected area (A) as a percentage of the whole body.

皮膚科劉權毅醫師 發表在 痞客邦 PIXNET 留言(0) 人氣()

中央廣播電台:2011/06/07
根據6日發表的一項統合分析報告,帕金森氏症(Parkinson's disease)患者所面臨的致命皮膚癌--黑色素瘤風險,為常人的2倍。

皮膚科劉權毅醫師 發表在 痞客邦 PIXNET 留言(0) 人氣()